Post-transplant Management in Heart Transplant Recipients: New Drugs and Prophylactic Strategies

AbstractPurpose of reviewToday, heart transplant offers a 1-year survival of 91% to select patients with end-stage heart failure. Since the implementation of heart allocation system change in Oct 2018, transplantation needs have to be met in critically ill candidates with high waitlist mortality. This brings forth the contemporary challenges of use of more patients bridged from mechanical circulatory support, use of marginal hearts, older donor age, allosensitization, donation after circulatory death, and hepatitis C-positive donors.Recent findingsAdvances in rejection surveillance and diagnosis, immunosuppression, and prophylaxis have no doubt increase the median survival post-heart transplant. However, long-term complications of malignancy, infections, and coronary allograft vasculopathy continue to threaten longevity. Evolving therapeutics in autoimmune diseases and cancer immunotherapy has generated much needed interest and research in antibody-mediated rejection pathways targeting B cells, plasma cells, cytokines, pathologic antibodies, and complement mechanisms.SummaryRecent innovations in diagnosis of rejection via peripheral gene expression profiling, improved surveillance of complications, and novel immunosuppression medications hold tremendous promise in the contemporary landscape of heart transplantation.
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research

Related Links:

The cancer organization today largely reinstated its former advice that men with low-risk prostate cancer be offered active surveillance as the lone'preferred'initial treatment option.News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Cancer Gene Therapy, Published online: 01 December 2021; doi:10.1038/s41417-021-00402-9Correction: microRNA-let-7e in serum-derived exosomes inhibits the metastasis of non-small-cell lung cancer in a SUV39H2/LSD1/CDH1-dependent manner
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
Today's materials from the Intraclear Biologics team may be of interest to those following the development of senolytic therapies. Since the Mayo Clinic has yet to publish results from their clinical trials of fisetin as a senolytic therapy, and may not do so for a few years yet, it is good to see even preliminary data from other sources. Senolytic therapies selectively destroy senescent cells, though only one approach (the combination of dasatinib and quercetin) has been definitely shown to destroy significant numbers of senescent cells in humans. Data has yet to be published on whether fisetin performs as well in humans ...
Source: Fight Aging! - Category: Research Authors: Tags: Self-Experimentation Source Type: blogs
Late-phase clinical trials that are currently recruiting patients with noncolorectal gastrointestinal (GI) cancers could be of benefit to your patients.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
Child and adolescent survivors of cancer —particularly those experiencing cognitive problems—may be at higher risk of suicidal thoughts than other youth their age, suggests areport inPsycho-Oncology.“Survivors of pediatric cancer are at elevated risk for both neurocognitive and psychological difficulties following cancer treatment,” wrote Christina M. Sharkey, Ph.D., of Children’s National Hospital in Washington, D.C., and colleagues. Studies of adult cancer survivors suggest there may be a link between neurocognitive deficits and suicidal ideation, but little is known of whether such deficits...
Source: Psychiatr News - Category: Psychiatry Tags: adolescents behavioral regulation children cognitive problems inattention IQ parents pediatric cancer processing speed psycho-oncology suicidal ideation teachers working memory Source Type: research
This study sought to design and validate a  nomogram capable of predicting outcomes in extensive-stage small-cell lung cancer (ES-SCLC) patients with superior vena cava syndrome (SVCS) based upon the timing of their radiotherapy treatment.MethodsWe retrospectively analyzed data from 175 ES-SCLC patients with SCVS, comparing outcomes between those that underwent upfront thoracic radiotherapy (initial radiotherapy with simultaneous chemotherapy) and those that underwent consolidative thoracic radiotherapy (following 4 –6 cycles of chemotherapy). Significant predictors of patient outcomes were identified using...
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
ConclusionMagnetic Resonance Image (MRI) linac-based planning for HNC is already feasible with good quality. Generally, an increased number of segments and increasing planning experience are able to provide better results regarding planning quality without significantly prolonging overall treatment time.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
00:00 to 02.26—Dr. Bihari gives his background and credentials. Dr. Bihari: My medical training started at Harvard Medical School. I graduated in 1957. Then I trained in Internal Medicine at one of the Harvard teaching hospitals in Boston, Beth Israel, and then in Neurology at Massachusetts General in Boston. Then I went to the National Institutes of Health for two years doing brain physiology—brain research. I did another residency training in Psychiatry in New York, at Columbia Presbyterian Medical Center and then, over the following five or six years, I got very involved in working in Drug Addiction. By 197...
Source: HONEST MEDICINE: My Dream for the Future - Category: Consumer Health News Authors: Tags: Anecdotal Treatments HONEST MEDICINE Integrative Medicine Low Dose Naltrexone Obituaries Source Type: blogs
More News: Autoimmune Disease | Bone Graft | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Genetics | Heart | Heart Failure | Heart Transplant | Hepatitis | Hepatitis C | Immunotherapy | Transplant Surgery | Transplants